- Page 2/6
Signal
Opinion
Expert
HOLD
HOLD
November 30, 2018
They have raised dividends, which signals confidence by management – who also owns the majority of shares. It has a service advantage and get loan turnarounds quickly. Brokers have technological advantages and there is reoccurring capital. Once a mortgage is closed it becomes highly visible and it shows the cash flow path.
Show full opinionHide full opinion
They have raised dividends, which signals confidence by management – who also owns the majority of shares. It has a service advantage and get loan turnarounds quickly. Brokers have technological advantages and there is reoccurring capital. Once a mortgage is closed it becomes highly visible and it shows the cash flow path.
BUY
BUY
November 30, 2018
He likes most of the Brookfield holdings and owns the parent company. Its payout ratio is about 80%, but sees the dividend as safe. It is soundly run and trades at a discount to NAV. A great long term holding. Yield 6.5%.
Show full opinionHide full opinionHe likes most of the Brookfield holdings and owns the parent company. Its payout ratio is about 80%, but sees the dividend as safe. It is soundly run and trades at a discount to NAV. A great long term holding. Yield 6.5%.
STRONG BUY
STRONG BUY
November 30, 2018
This is a core holding for him. The value of the real estate holdings alone are $200 per share. It is a hard company to value as half the company is recurring revenue and half is land sales. He is not sure how price reconnects with value – perhaps a matter of time.
Show full opinionHide full opinionThis is a core holding for him. The value of the real estate holdings alone are $200 per share. It is a hard company to value as half the company is recurring revenue and half is land sales. He is not sure how price reconnects with value – perhaps a matter of time.
WATCH
WATCH
November 30, 2018
It is a binary situation. If anyone can turn around the company it is the new CEO – his track record is incredible. The power division remains weak and the capital side is under reserved. He would wait to see improvement.
Show full opinionHide full opinionIt is a binary situation. If anyone can turn around the company it is the new CEO – his track record is incredible. The power division remains weak and the capital side is under reserved. He would wait to see improvement.
COMMENT
COMMENT
November 30, 2018
This is one of two spin offs from Honeywell. This company is less than 1% of the market cap of Honeywell. It trades at less than 3 times earnings. One of the overhangs relates to asbestos in the brakes division. The low PE foretells doom. The company has top market share in auto turbo-chargers and that segment is growing.
Show full opinionHide full opinionThis is one of two spin offs from Honeywell. This company is less than 1% of the market cap of Honeywell. It trades at less than 3 times earnings. One of the overhangs relates to asbestos in the brakes division. The low PE foretells doom. The company has top market share in auto turbo-chargers and that segment is growing.
TOP PICK
TOP PICK
November 30, 2018
He likes it because nobody likes it. It is former Valiant Pharmaceuticals and trades at 6 times cash-flow. He encourages investors to look beyond its checkered past. It has high quality recurring cash-flows in the contact lens division. Every division is growing organically. It does have a high debt load, but the trajectory of cash flow will elevate that risk. Yield 0%. (Analysts’ price target is $35.39)
Show full opinionHide full opinionHe likes it because nobody likes it. It is former Valiant Pharmaceuticals and trades at 6 times cash-flow. He encourages investors to look beyond its checkered past. It has high quality recurring cash-flows in the contact lens division. Every division is growing organically. It does have a high debt load, but the trajectory of cash flow will elevate that risk. Yield 0%. (Analysts’ price target is $35.39)
TOP PICK
TOP PICK
November 30, 2018
This company is involved in colonoscopies and aggregates businesses in that space, mostly in the US. It trades at less than 10 times free cash-flow. He expects growth from organic tail winds in the procedure space. Acquisitions are done within existing cash flow. Yield 0%. (Analysts’ price target is $6.08)
Show full opinionHide full opinionThis company is involved in colonoscopies and aggregates businesses in that space, mostly in the US. It trades at less than 10 times free cash-flow. He expects growth from organic tail winds in the procedure space. Acquisitions are done within existing cash flow. Yield 0%. (Analysts’ price target is $6.08)
